Parenteral vitamin B12 reduces hyperhomocysteinemia in end-stage renal disease

Clinical and Investigative Medicine

Volumn 24, Issue 1, 2001, Pages 5-11

  Kaplan, L N ^a   Mamer, O A ^a   Hoffer, L J ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Clinical trials, phase 2; Folic acid; Hemodialysis; Homocysteine; Hyperhomocysteinemia; Kidney failure, chronic; Methylmalonic acid; Pyridoxine; Vitamin B 12

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; CYSTEINE; HOMOCYSTEINE; METHYLMALONIC ACID;

AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; HEMODIALYSIS; HOMOCYSTINURIA; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION; BLOOD; CHRONIC KIDNEY FAILURE; RENAL REPLACEMENT THERAPY; SUBCUTANEOUS DRUG ADMINISTRATION;

CYSTEINE; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; INJECTIONS, SUBCUTANEOUS; KIDNEY FAILURE, CHRONIC; METHYLMALONIC ACID; RENAL DIALYSIS; VITAMIN B 12;

EID: 0034745415     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Hyperhomocysteinemia in end-stage renal disease: Prevalence, etiology, and potential relationship to arteriosclerotic outcomes
2. Major determinants of hyperhomocysteinemia in peritoneal dialysis patients
3. Hyperhomocysteinemia, hyperfibrinogenemia, and lipoprotein (a) excess in maintenance dialysis patients: A matched case-control study
4. Homocysteinemia and vascular disease in end-stage renal disease
5. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease
6. Plasma total homocysteine and hemodialysis access thrombosis: A prospective study
7. Homocysteine and vascular disease
8. Homocysteine and atherothrombosis
9. 6, and cardiovascular disease
10. Riboflavin as a determinant of plasma total homocysteine: Effect modification by the methylenetetrahydrofolate reductase C677T polymorphism
11. Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients
12. The role of homocysteine in end-stage renal disease
13. High dose-B-vitamin treatment of hyperhomocysteinemia in dialysis patients
14. A tale of two homocysteines - And two hemodialysis units
15. 12
16. Effective treatment of cobalamin deficiency with oral cobalamin
17. Controlled comparison of L-5-methyltetrahydrofolate versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients
18. Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection
19. Determination of total homocysteine in human plasma by isocratic high-performance liquid chromatography
20. Novel reductant for determination of total plasma homocysteine
21. Determination of methylmalonic acid in biological fluids by mass spectrometry
22. Enhanced reduction of fasting total homocysteine levels with supraphysiological versus standard multivitamin dose folic acid supplementation in renal transplant recipients
23. Total homocysteine and cardiovascular disease
24. Intravenous methylcobalamin treatment for uremic and diabetic neuropathy in chronic hemodialysis patients
25. Renal uptake and excretion of homocysteine in rats with acute hyperhomocysteinemia
26. No net renal extraction of homocysteine in fasting humans
27. Homocysteine and methionine metabolism in ESRD: A stable isotope study
28. Methylmalonic acid in renal insufficiency: Evidence of accumulation and implications for diagnosis of cobalamin deficiency
29. Serum methylmalonic acid in uraemia
30. 12 decreases homocysteine and methylmalonic acid but also serum folate in patients with end-stage renal disease
31. Plasma homocysteine in renal failure
32. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations